Product Search

  • Renal Anemia
    DecisionBase, May, 2015

    Renal anemia is one of the primary complications of chronic kidney disease (CKD) and is treated with erythropoiesis-stimulating agents (ESAs) and oral/IV iron....

  • Cancer Immunotherapies - 2015
    Special Reports, May, 2015

    Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative...

  • LaunchTrends®: Keytruda Wave 2 (US)
    LaunchTrends, May, 2015

    LaunchTrends: Keytruda (Wave 2) is the second in a series of syndicated reports designed to track the physician perception, uptake, and competitive...

  • Taking the Pulse® U.S. 2015 Strategic Insight Report
    Taking the Pulse U.S., May, 2015

    Each Strategic Insight expands upon a key trend or topic from Taking the Pulse® U.S. in an easy-to-read, informative way. Taking the Pulse U.S. is Manhattan...

  • Parkinson’s Disease (Intermediate to Advanced)
    DecisionBase, May, 2015

    The prevalence of Parkinson’s disease (PD) will approach 3 million cases in the major pharmaceutical markets by 2023. A substantial portion of PD patients fall...

  • Taking the Pulse® Formulary Decision Makers 2015
    Taking the Pulse U.S., May, 2015

    Taking the Pulse® U.S. is Manhattan Research's annual market research study and syndicated advisory service focused on studying to what extent formulary...

  • Type 2 Diabetes
    DecisionBase, May, 2015

    Affecting 30 million people in the Unites States alone, type 2 diabetes is a critical public health concern. Although diet and exercise are key initial and...

  • Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    U.S. Physician and Payer Forum, May, 2015

    The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the United States is centered on the use...

  • Cybercitizen Health® U.S. 2014 Strategic Insight Report
    Cybercitizen Health U.S., May, 2015

    Cybercitizen Health U.S. is Manhattan Research's annual market research study and syndicated advisory service benchmarking how U.S. consumers use the Internet,...

  • ChartTrends®: Nephrology in Dialysis (EU5) 2015
    ChartTrends, May, 2015

    This report leverages physician insights, as well as a year’s worth of patient chart data, to provide the most up-to-date information about dialysis patient...

  • Breast Cancer (Advanced/Metastatic, HR-Positive, HER2-Negative)
    DecisionBase, May, 2015

    Drug development for advanced/metastatic, hormone-receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer has gained...

  • Acute Heart Failure
    DecisionBase, May, 2015

    Acute heart failure (AHF) is one of the leading causes of hospitalization in the developed world, representing a significant healthcare burden. Treatment of...

  • Current and Emerging Small-Molecule Targeted Agents in Key Oncology Indications
    Emerging Markets Physician and Payer Forum, May, 2015

    Small molecule therapies offer specific targeting of the aberrant cellular signaling that underlies a certain cancer, without the nonspecific and often less...

  • TreatmentTrends®: Breast Cancer Q2 2015 (US)
    TreatmentTrends, May, 2015

    TreatmentTrends®: Breast Cancer Q2 2015 (US) in the first in a series of reports that examine current trends in the management of advanced/metastatic breast...

  • LaunchTrends:® Lemtrada Wave 2 (US)
    LaunchTrends, May, 2015

    LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent,...

  • LaunchTrends:® Ibrance Wave 1 (US)
    LaunchTrends, May, 2015

    LaunchTrends: Ibrance (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive...

  • Market Access Dynamics in Opioid Addiction
    EU Physician and Payer Forum, May, 2015

    Nearly 800,000 individuals were diagnosed with opioid addiction in the five major European markets in 2014. The treatment strategy for patients with opioid...

  • Rheumatoid Arthritis
    DecisionBase, May, 2015

    Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral kinase inhibitor (tofacitinib [Pfizer/Takeda Pharmaceutical’s Xeljanz])....

  • Positioning of Current and Emerging Agents for Alcohol Addiction in the EU5
    EU Physician and Payer Forum, May, 2015

    Despite being a leading preventable cause of morbidity and mortality in Europe, alcohol addiction is tremendously underdiagnosed and undertreated....

  • TreatmentTrends®: Pulmonary Arterial Hypertension 2015 (US)
    TreatmentTrends, May, 2015

    Pulmonary arterial hypertension (PAH) is a severe and debilitating disease with rapid progression and high rates of mortality. If left untreated, life...

Displaying results 1-20 (of 1974)
 |<  < 1 2 3 4 5 6 7 8 9 10  >  >| 

Search Reports

Decision Resources Group brands include: